14.10.2021 – 17:59
SUNNYVALE, CALIFORNIA (ots)
The new “plus” version of the test optimizes the detection of future SARS-CoV-2 variants through an additional, third gene target
Cepheid announced today that it has CE Marked for the Xpert Xpress CoV-2 / Flu / RSV plus-Test had received.
This is a molecular diagnostic rapid PCR test from a single one
Patient sample for the qualitative detection of those viruses that cause COVID-19 or infections with influenza A, influenza B and the respiratory syncytial virus (RSV). The new plusVersion of the test offers a third gene target for the detection of SARS-CoV-2 to address the challenge of future virus mutations. The Xpert Xpress CoV-2 / Flu / RSV plus is designed for use on one of the more than 35,000 GeneXpert® systems from Cepheid installed worldwide and delivers results in approx. 36 minutes.
Several variants of the virus causing COVID-19 were documented around the world during the pandemic. Viruses change constantly as a result of mutations and it is expected that further new variants will also appear in the future. With the additional third gene target, the plus-Version of the CoV-2 / Flu / RSV test from Cepheid provides a broader coverage, which is intended to mitigate the possible effects of a future genetic drift of the virus.
“During this season of respiratory disease, healthcare facilities can face a wide variety of viral infections, with symptoms mimicking those of
COVID-19 overlap, as does Influenza A, Influenza B, and the Respiratory Syncytial Virus. The availability of a quick and accurate test that can detect current and future variants of the viruses that cause COVID-19 and influenza is becoming increasingly important, “said Dr. David Persing, Chief Medical and Technology Officer at Cepheid.” Performing a single, highly sensitive multiplex test that detects and differentiates all four viruses on a single sample provides meaningful results that enable better decisions to be made at the forefront of our healthcare systems. “
Der Xpert Xpress CoV-2 / Flu / RSV more-Test is expected to start shipping this week to countries that accept CE marked products.
Under https://www.cepheid.com/de you will find more information, videos and leaflets.
– More –
Cepheid is a leading company in the field of molecular diagnostics based in Sunnyvale / California (USA). Cepheid is committed to better health care by developing, manufacturing, and distributing accurate, yet easy-to-use molecular systems and tests. The company offers solutions for facilities of all sizes to automate highly complex and time-consuming manual work steps. This enables sophisticated molecular diagnostic tests to be performed on a wide range of organisms and genetic diseases. With its extensive capabilities in the field of molecular biology, the company focuses on those applications where accurate, fast and actionable test results are particularly important, e.g. B. in the treatment of infectious diseases and cancer. For more information, see http://www.cepheid.com/de.
Contact for media inquiries:
Original content from: News Direct, transmitted by news aktuell